首次!四部门联合发文:中医药人才培养要有“独狼”精神!

2022-06-28 中医药局网站 中医药局网站

培养造就中医药领域战略科学家,打造中医药人才发展高地!

近日,国家中医药管理局、教育部、人力资源社会保障部、国家卫生健康委联合印发《关于加强新时代中医药人才工作的意见》(以下简称《意见》),聚焦人才培养、使用、评价、激励等体制机制改革提出相关政策措施,推动新时代中医药人才工作高质量发展。

图片

据悉,该《意见》是首个多部门共同出台的系统部署中医药人才工作的政策性文件。

高层次人才是中医药人才队伍的“头雁”

用“独狼”精神,加快培养集聚高层次人才

《意见》提出,培养造就中医药领域战略科学家,在院士评选、国家重大人才工程等高层次人才评选中,探索中医药人才单列计划、单独评价,注重发现和推介中医药优秀人才。到2035年,中医药领域战略科学家、领军人才、创新团队不断涌现。

逐步扩大本科层次中医专业农村订单定向免费医学生招生规模,持续开展全国基层名老中医药专家传承工作室建设,到2025年,为每个二级以上县级中医医疗机构建立1-2个传承工作室。

面向基层医疗机构医师和乡村医生开展中医药知识技能全员培训,用5年左右时间实现培训全覆盖。对本科及以上学历,经中医全科专业规范化培训合格并到基层医疗卫生机构工作的,可直接参加中级职称考试,考试通过的直接聘任中级职称。

《意见》明确,在院士评选、国家重大人才工程等高层次人才评选中,探索中医药人才单列计划、单独评价。面向国家重大项目、国家实验室、全国重点实验室、国家重大人才计划等,吸引、发现、造就若干具有卓越科技组织领导才能的战略科学家。

进一步实施中医药领军人才支持计划,持续支持岐黄学者等各类高层次人才培养项目,对领军人才实行人才梯队配套、科研条件配套、管理机制配套等特殊政策,培养造就一批中医临床大家和科技领军人才。建立健全面向青年人才普惠性支持措施,在重点人才项目、重大科技立项等工程计划中设立青年人才支持专项,促进青年人才脱颖而出。

加大力度支持京津冀、长三角、粤港澳大湾区、黄河流域等中医药优势资源较为集中的区域,建设中医药高层次人才中心和创新高地。

做到“能西会中”

大力推进西医学习中医

为了让群众在家门口看上好中医,《意见》提出,到2025年,实现二级以上公立中医医院中医医师配置不低于本机构医师总数的60%,全部社区卫生服务中心和乡镇卫生院设置中医馆、配备中医医师;社区卫生服务站至少配备1名中医类别医师或能够提供中医药服务的临床类别医师;80%以上的村卫生室至少配备1名能够提供中医药服务的医务人员。

《意见》还明确,大力推进西医学习中医。综合医院、专科医院、传染病医院、妇幼保健等机构应支持西医医师接受中医药专业知识培训,逐步做到“能西会中”。实施西医学习中医专项,力争用5至10年时间,培养一批高层次中西医结合人才。

医教协同深化中医药教育改革

拓宽中医医疗服务岗位

《意见》明确,突出中医药发展和区域经济社会发展需求导向,调整优化中医药学科专业和区域布局。加大中西部、省部局共建中医药院校支持力度,引导有条件高校稳步扩大中医药类专业博士招生计划。

同时,强化中医医院育人职能,核增临床师资、教育管理岗位,实施中医临床教学基地建设专项,实施卓越中医药师资培训计划,完善中医药人才培养模式。面向中医学类专业全面推行院校—师承教育相结合的教育模式,改革中医医师规范化培训模式,完善中医药继续教育制度。

《意见》还提出,要拓宽中医医疗服务岗位,三级综合医院按照要求设置中医门诊和中医病房,床位数不低于医院标准床位数的5%。鼓励临床科室配备一定数量的中医医师,允许中医医师在临床科室按照注册执业范围开展与其执业范围相符的诊疗活动。完善国医大师、全国名中医周期性评选表彰机制,定期评选表彰一批国医大师、全国名中医。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1796813, encodeId=fdc81e9681326, content=<a href='/topic/show?id=0f9f2149803' target=_blank style='color:#2F92EE;'>#中医药人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21498, encryptionId=0f9f2149803, topicName=中医药人才培养)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat May 13 21:56:11 CST 2023, time=2023-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796802, encodeId=9e061e96802d7, content=<a href='/topic/show?id=490e2149e82' target=_blank style='color:#2F92EE;'>#中医药人才#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21497, encryptionId=490e2149e82, topicName=中医药人才)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Aug 12 11:56:11 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410230, encodeId=cd30141023085, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469615, encodeId=958a146961568, content=<a href='/topic/show?id=ee4a352e18a' target=_blank style='color:#2F92EE;'>#医药人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35271, encryptionId=ee4a352e18a, topicName=医药人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc517042865, createdName=limedical1976, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554896, encodeId=c66f1554896dd, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1796813, encodeId=fdc81e9681326, content=<a href='/topic/show?id=0f9f2149803' target=_blank style='color:#2F92EE;'>#中医药人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21498, encryptionId=0f9f2149803, topicName=中医药人才培养)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat May 13 21:56:11 CST 2023, time=2023-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796802, encodeId=9e061e96802d7, content=<a href='/topic/show?id=490e2149e82' target=_blank style='color:#2F92EE;'>#中医药人才#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21497, encryptionId=490e2149e82, topicName=中医药人才)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Aug 12 11:56:11 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410230, encodeId=cd30141023085, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469615, encodeId=958a146961568, content=<a href='/topic/show?id=ee4a352e18a' target=_blank style='color:#2F92EE;'>#医药人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35271, encryptionId=ee4a352e18a, topicName=医药人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc517042865, createdName=limedical1976, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554896, encodeId=c66f1554896dd, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1796813, encodeId=fdc81e9681326, content=<a href='/topic/show?id=0f9f2149803' target=_blank style='color:#2F92EE;'>#中医药人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21498, encryptionId=0f9f2149803, topicName=中医药人才培养)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat May 13 21:56:11 CST 2023, time=2023-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796802, encodeId=9e061e96802d7, content=<a href='/topic/show?id=490e2149e82' target=_blank style='color:#2F92EE;'>#中医药人才#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21497, encryptionId=490e2149e82, topicName=中医药人才)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Aug 12 11:56:11 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410230, encodeId=cd30141023085, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469615, encodeId=958a146961568, content=<a href='/topic/show?id=ee4a352e18a' target=_blank style='color:#2F92EE;'>#医药人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35271, encryptionId=ee4a352e18a, topicName=医药人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc517042865, createdName=limedical1976, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554896, encodeId=c66f1554896dd, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=)]
    2022-06-30 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1796813, encodeId=fdc81e9681326, content=<a href='/topic/show?id=0f9f2149803' target=_blank style='color:#2F92EE;'>#中医药人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21498, encryptionId=0f9f2149803, topicName=中医药人才培养)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat May 13 21:56:11 CST 2023, time=2023-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796802, encodeId=9e061e96802d7, content=<a href='/topic/show?id=490e2149e82' target=_blank style='color:#2F92EE;'>#中医药人才#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21497, encryptionId=490e2149e82, topicName=中医药人才)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Aug 12 11:56:11 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410230, encodeId=cd30141023085, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469615, encodeId=958a146961568, content=<a href='/topic/show?id=ee4a352e18a' target=_blank style='color:#2F92EE;'>#医药人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35271, encryptionId=ee4a352e18a, topicName=医药人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc517042865, createdName=limedical1976, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554896, encodeId=c66f1554896dd, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1796813, encodeId=fdc81e9681326, content=<a href='/topic/show?id=0f9f2149803' target=_blank style='color:#2F92EE;'>#中医药人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21498, encryptionId=0f9f2149803, topicName=中医药人才培养)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Sat May 13 21:56:11 CST 2023, time=2023-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796802, encodeId=9e061e96802d7, content=<a href='/topic/show?id=490e2149e82' target=_blank style='color:#2F92EE;'>#中医药人才#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21497, encryptionId=490e2149e82, topicName=中医药人才)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Fri Aug 12 11:56:11 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410230, encodeId=cd30141023085, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469615, encodeId=958a146961568, content=<a href='/topic/show?id=ee4a352e18a' target=_blank style='color:#2F92EE;'>#医药人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35271, encryptionId=ee4a352e18a, topicName=医药人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc517042865, createdName=limedical1976, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554896, encodeId=c66f1554896dd, content=<a href='/topic/show?id=023b249083e' target=_blank style='color:#2F92EE;'>#人才培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24908, encryptionId=023b249083e, topicName=人才培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056914558248, createdName=jml2014, createdTime=Thu Jun 30 00:56:11 CST 2022, time=2022-06-30, status=1, ipAttribution=)]

相关资讯

探报24H:苏州发现奥密克戎新变异株;中医药能有效治疗新冠

生物探索与您一同关注“药”闻,探索生物科技的价值!

中医治疗的食管癌,出路在哪里?

食管癌 (EC) 是全球癌症相关死亡的第六大原因。西医在其治疗中发挥了主导作用,但其预后仍不理想。

系统评价和荟萃分析:中医药联合化疗治疗乳腺癌

乳腺癌是我国女性常见的恶性肿瘤,其年发病率持续上升。每年大约有 280,000 例新发乳腺癌病例,乳腺癌是女性的头号杀手。近年来,紫杉类和蒽环类药物联合应用中药化疗,延长了乳腺癌患者的生存时间。

系统评价和荟萃分析方案:中医健脾疗法治疗运动性疲劳

运动性疲劳(EIF)是体育比赛和训练中常见的现象。可能会给运动员的运动技能执行和认知带来麻烦。

Front Pharmacol:舒泻一号汤通过IL-6/JAK2/STAT3信号通路减轻慢性轻度不可预见性应激诱导的肝损伤

探讨舒泻一号汤治疗慢性应激性大鼠抑郁样行为和肝损伤的作用及其机制。

J Ethnopharmacol:清热中药注射剂治疗AECOPD疗效比较

慢性阻塞性肺疾病急性加重 (AECOPD) 被定义为以 COPD 患者呼吸道症状恶化为特征的严重事件,并且是全球主要的死亡原因之一。其病情危重,而且 AECOPD 的医疗经济负担突出。